Abbokinase (Urokinase) - Drug Interactions, Contraindications, Overdosage

DRUG INTERACTIONS

Anticoagulants and agents that alter platelet function (such as aspirin, other non-steroidal anti-inflammatory agents, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of serious bleeding.

Administration of Abbokinase® prior to, during, or after other thrombolytic agents may increase the risk of serious bleeding.

Because concomitant use of Abbokinase® with agents that alter coagulation, inhibit platelet function, or are thrombolytic may further increase the potential for bleeding complications, careful monitoring for bleeding is recommended.

The interaction of Abbokinase® with other drugs has not been studied and is not known.

CONTRAINDICATIONS

The use of Abbokinase® is contraindicated in patients with a history of hypersensitivity to the product (see WARNINGS and ADVERSE REACTIONS).

Because thrombolytic therapy increases the risk of bleeding, Abbokinase® is contraindicated in the situations listed below (see WARNINGS).

• Active internal bleeding
• Recent (e.g., within two months) cerebrovascular accident
• Recent (e.g., within two months) intracranial or intraspinal surgery
• Recent trauma including cardiopulmonary resuscitation
• Intracranial neoplasm, arteriovenous malformation, or aneurysm
• Known bleeding diatheses
• Severe uncontrolled arterial hypertension